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Abstract
Aims/hypothesis Several publications suggest an associa-
tion between certain types of insulin and cancer, but with
conflicting results. We investigated whether insulin glargine
(A21Gly,B31Arg,B32Arg human insulin) is associated with
an increased risk of cancer in a large population-based
cohort study.
Methods Data for this study were obtained from dispensing
records from community pharmacies individually linked to
hospital discharge records from 2.5 million individuals in the
Netherlands. In a cohort of incident users of insulin, the
association between insulin glargine and other insulin ana-
logues, respectively, and cancer was analysed in comparison
with human insulin using Cox proportional hazard models with
cumulative duration of drug use as a time-varying determinant.
The first hospital admission with a primary diagnosis of cancer
was considered as the main outcome; secondary analyses were
performed with specific cancers as outcomes.
Results Of the 19,337 incident insulin users enrolled, 878
developed cancer. Use of insulin glargine was associated
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with a lower risk of malignancies in general in comparison
with human insulin (HR 0.75, 95% CI 0.71, 0.80). In
contrast, an increased risk was found for breast cancer (HR
1.58, 95% CI 1.22, 2.05). Dose–response relationships
could not be identified.
Conclusion/interpretation Users of insulin glargine and
users of other insulin analogues had a lower risk of cancer
in general than those using human insulin. Both associa-
tions might be a consequence of residual confounding, lack
of adherence or competing risk. However, as in previous
studies, we demonstrated an increased risk of breast cancer
in users of insulin glargine in comparison with users of
human insulin.
Keywords Breast cancer . Cancer . Insulin . Insulin
analogues . Insulin glargine
Abbreviations
ATC Anatomical therapeutic chemical
DDD Defined daily dose
OGLD Oral glucose-lowering drug
PHARMO RLS PHARMO Record Linkage System
Introduction
Diabetes mellitus is an important risk factor for cardiovascular
disease [1, 2]. In addition, diabetes has been associated with
an increased risk of colorectal cancer [3, 4], breast cancer [4,
5], endometrial cancer [4, 6], hepatocellular carcinoma [4, 7],
pancreatic cancer [4, 8] and bladder cancer [4, 9]. In contrast,
patients with diabetes have a decreased risk of developing
prostate cancer [4, 10]. Furthermore, diabetes has been
reported as an independent predictor of mortality from
cancer [4, 11, 12]. However, due to factors such as duration
of diabetes, different drugs used to attain metabolic control
and presence of other diseases, the assessment of cancer risk
in diabetes patients remains difficult [13, 14].
In 2004, a publication with data from the General Practice
Research Database in the UK reported that in patients with
type 2 diabetes, chronic insulin therapy was associated with a
significantly higher risk of colorectal cancer compared with
patients with diabetes who did not use insulin [15]. By the end
of 2009, articles were published using data from population
registries to analyse a possible relationship between the use
of hypoglycaemic agents and the risk of cancer [16–19]. Of
these, three showed an increased risk of cancer with use of
insulin glargine (A21Gly,B31Arg,B32Arg human insulin)
compared with other types of insulin analogues or human
insulin [16, 18, 19]. Currie et al. did show an increased risk
of cancer while using insulin compared with patients using
metformin but did not show an increased risk of cancer for
those using insulin analogues compared with those using
human insulin [17]. More recently, it has been reported that
the use of insulin glargine did not increase the risk of overall
cancer compared with the use of human insulin [20].
In addition to these observational studies, reports
regarding randomised controlled trials have been published
[21–23]. None of these described dissimilarity in cancer
incidence between participants treated with insulin glargine
and those treated with human insulin or other types of
insulin [21–23]. With regard to dose, a dose-dependent
relationship has been described for insulin glargine and risk
of cancer, but not for other insulin analogues or human
insulin [18, 24]. Consequently, whether different types of
insulin may be a cause of cancer is an issue of ongoing
debate [25–32].
Therefore, the objective of this study was to analyse the
hypothesis that use of insulin glargine is associated with an
increased risk of cancer in comparison with use of human
insulin.
Methods
Setting
Data for this study were obtained from the PHARMO Record
Linkage System (PHARMO RLS), which includes drug-
dispensing records from community pharmacies linked on a
patient level to hospital discharge records from the Dutch
National Medical Register for approximately 2.5 million
individuals in the Netherlands since 1986 [33, 34].
The drug-dispensing database contains the following
information per prescription as of 1998: anatomical
therapeutic chemical (ATC) classification of the drug,
dispensing date, regimen, quantity dispensed and estimated
duration of use [35]. The hospital record database contains
detailed information concerning primary and secondary
discharge diagnoses and dates of admission and discharge.
All diagnoses are coded according to the International
Classification of Disease, ninth edition (ICD-9) [36].
Study population
All participants with a prescription for any hypoglycaemic
agent, including an oral glucose-lowering drug (OGLD) or
insulin, between 1 January 1998 and 31 December 2008
were included in the study cohort. The patient flow is
presented visually in a flow diagram (Fig. 1). As insulin
glargine has been marketed in the Netherlands since June
2000, participants with a prescription of any insulin before
1 June 2000 were excluded from the cohort [37].
Furthermore, to ensure the study cohort included only
incident insulin users, users needed to have had a 6 month
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period without prescription of insulin (any type) before
inclusion. To mimic a study cohort of participants with type
2 diabetes, those using only insulin were assumed to have
type 1 diabetes and were excluded from the analysis. In
158,599 participants within the PHARMO RLS were prescribed
an OGLD or insulin between 1 January 1998
and 31 December 2008  
3,184 (2.0%) were excluded due to 
inconsistencies of dates in the database 
11 participants (<0.01%) used beef or pork 
insulin. No participants were treated with 
inhalation insulin or with exenatide
99,401 (65.0%) participants were solely treated 
with OGLD 
2,581 (1.6%) were excluded for having a cancer 
diagnosis before 1 January 1998 
18,763 (12.3%) received their first insulin 
prescription before insulin glargine was 
marketed
11,294 (7.4%) participants did not have a 
prescription-free period of 6 months 
34,659 (22.7%) incident users were treated with 
insulin after 1 June 2000  
(participants could be excluded due to multiple 
reasons) 
19,377 (55.8%) participants were included in the 
study cohort
11,719 (33.8%) participants had their first
prescription for an insulin analogue other than
insulin glargine  
17,829 (51.4%) participants had their first 
prescription for human insulin 
5,111 (14.7%) participants had their first 
prescription for insulin glargine 
3,789 (74.1%) participants had their first 
prescription for insulin glargine 
6,032 (51.5%) participants had their first 
prescription for another insulin analogue than 
insulin glargine 
9,516 (53.4%) participants had their first 
prescription for human insulin 
281 participants (5.5%) were 
diagnosed with cancer before 
their first insulin prescription 
542 participants (4.6%) were 
diagnosed with cancer before 
their first insulin prescription 
798 participants (4.5%) were 
diagnosed with cancer before 
their first insulin prescription 
90 participants (1.8%) received 
their first dispensing <18 years 
434 participants (2.4%) received 
their first dispensing <18 years 
576 participants (4.9%) received 
their first dispensing <18 years 
1,090 (21.3%) users were solely
treated with insulin
(assumed to have type 1 diabetes)
7,742 (43.4%) users were solely
treated with insulin
(assumed to have type 1 diabetes)
5,268 (45.0%) users were solely
treated with insulin
(assumed to have type 1 diabetes)
Fig. 1 Flow chart visualising the flow of participants into the study cohort
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addition, participants with a primary cancer diagnosis
before 1 June 2000, a primary cancer diagnosis before
prescription of insulin, or who were aged under 18 years at
first prescription were excluded. As a consequence, the
remaining cohort only included insulin users with prior use
of OGLD who were followed over time starting from the
first prescription for insulin.
Exposure
The different types of insulin prescribed for diabetes were
classified into three mutually exclusive categories accord-
ing to ATC code: insulin glargine; other insulin analogues;
and human insulin (electronic supplementary material
[ESM] Table 1). For each participant, the number of
cumulative days of insulin use was calculated. The
cumulative exposure to each insulin category at any point
in time during follow-up was calculated for each participant
in days since start of the respective insulin type. Cumula-
tive days of insulin exposure were taken from this time
point until death of the participant, end of study, first
diagnosis of cancer, relocation out of the PHARMO RLS
catchment area, or the last day of use of a dispensed agent
in the same insulin category.
To visualise participants’ drug adherence with different
types of insulin, the percentage of participants adherent to
therapy was calculated. For every cohort member, the
follow-up time was calculated for insulin glargine, other
insulin analogues and human insulin, respectively. For
every month of follow-up, the number of users was divided
by the total number of those who started minus those who
died, those diagnosed with cancer and those who moved
out of the PHARMO RLS catchment area.
Outcome
The first hospital admission with a primary diagnosis of
any type of cancer, ICD-9 codes 140–172, 174–209 and
235–239, was considered the primary outcome [36]. The
secondary outcome measure was diagnosis of one of the
following solid cancers: colon cancer (ICD-9 153 or 154),
pancreatic cancer (ICD-9 157), breast cancer (ICD-9 174
or 175), prostate cancer (ICD-9 185), endometrial cancer
(ICD-9 179 or 182), respiratory tract cancer (ICD-9 160–
165) and bladder cancer (ICD-9 188). These cancers were
selected because they have been associated with diabetes,
either with an increased or with a decreased risk [3, 5, 6,
8–10].
Covariables
Age at first insulin prescription, sex, number of unique
other drugs used in the year before start of insulin
(excluding those prescribed for diabetes), number of
hospitalisations in the year before start of insulin and
calendar time were considered potential confounders or
effect modifiers. The number of days of use of OGLD in
the year before start of insulin therapy was calculated, as
well as the number of OGLDs used as of 1 January 1998
to adjust for duration of diabetes. Furthermore, the
average dose was calculated per insulin category as
average defined daily dose (DDD) over the previously
dispensed prescriptions to adjust for severity of glucose
intolerance. For all types of insulin, one DDD is
equivalent to 40 U insulin [35].
Statistical analysis
Calculation of cumulative exposure Individuals were
followed from their first insulin prescription until the first
of one of the following events: a cancer as defined above,
death, end of data collection in the PHARMO RLS (i.e. the
patient moves out of the PHARMO RLS area) or end of the
study period at 31 December 2008. The association
between insulin and cancer was analysed using Cox
proportional hazard models with duration of cumulative
drug use as a time-varying determinant, as described by
Stricker and Stijnen [38]. In this model, cumulative
exposure in participants with cancer at the date of diagnosis
is compared with cumulative exposure in all individuals
without cancer with the same duration of insulin exposure
in days. Time since start of insulin is used as the underlying
timescale in the Cox proportional hazards model. We
assumed that cancer risk after a certain cumulative exposure
does not return to zero after stopping (i.e. in case of
switching to another type of insulin). However, time since
cessation was taken into account in one of the sub-analyses.
In the analysis performed, the actual exposure during
follow-up was used. This analysis defines the exposure
accurately but may suffer from reverse causation bias. To
address this issue, analyses were performed taking into
account a latent period before the diagnosis of cancer in
which we assumed that cancer was already present 1 year
before it was actually diagnosed (for instance, cumulative
exposure to 21 June 2007 instead of 21 June 2008). To
further deal with the issue of reverse causation, a fixed-
cohort analysis was performed in which the first exposure
to insulin determined the drug category in which the
participant was categorised. To further address potential
residual confounding, a propensity-score analysis was
performed. The methods and results for the fixed and
propensity-score analyses are presented in, respectively,
ESM methods and results.
The ways in which use of OGLD and dose were
addressed in the analyses are described in ESM methods,
as are the general statistical methods used.
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Results
Setting and characteristics
Within the PHARMO RLS, 158,599 participants were pre-
scribed an OGLD or insulin between 1 January 1998 and 31
December 2008. After applying exclusion criteria, 19,337
(12.2%) participants were included in the study cohort (Fig. 1).
As can be seen from Table 1, there were significant
differences at baseline and during follow-up between
participants starting on insulin glargine or other insulin
analogues and those starting on human insulin. Users of
insulin analogues were significantly younger than those
starting on insulin glargine; in contrast, those starting on
insulin glargine were more frequently male than those
starting on other insulin analogues. The mean number of
unique other drugs used and number of hospitalisations in
the year before start of insulin did not differ significantly.
The first dose prescribed, as well as the average dose
calculated over all prescriptions, was significantly lower for
those using other insulin analogues in comparison with
those using insulin glargine. The duration of OGLD use
prior to start of insulin was significantly shorter for those
using other insulin analogues than for those using insulin
glargine or human insulin. However, when stratifying for
the year in which insulin therapy was started, no clear
differences could be seen (ESM Table 2). Last, the duration
of days of follow-up since the start of insulin was considerably
lower for users of insulin glargine than for those using other
insulin analogues. An adherence curve is presented in Fig. 2 in
which the percentages of participants adherent to the three
different categories of insulin are visualised. Those dispensed
insulin glargine were statistically significantly less adherent
to therapy than those dispensed other insulin analogues or
human insulin. In ESM Fig. 1 (insulin glargine), ESM Fig. 2
(other insulin analogues) and ESM Fig. 3 (human insulin)
adherence is presented separately for those who died, those
who got diagnosed with cancer and those who were censored
at the end of study.
As-treated analyses
Of the 878 participants hospitalised for cancer, 158 were
treated with insulin glargine, 423 with other insulin
analogues and 592 participants were treated with human
insulin. The corresponding incidence rates were, respec-
tively, 11.29, 13.78 and 12.81 cancers per 1,000 patient
years. As can be seen from Table 2, use of insulin glargine
was associated with a lower risk of malignancies in
comparison with use of human insulin (HR 0.71, 95% CI
0.67, 0.75). In the full model, adjustments did not change
the HR (HR 0.75, 95% CI 0.71, 0.80). Stratifying for prior
OGLD use for less or longer than 1 year did not change this
point estimate nor did adjustment for prior days of OGLD
used change the point estimates by more than 10%.
Adjustments were made by adding dose as an additional
time-varying covariable to the model (HR 0.75, 95% CI
0.71, 0.80) but, as follow-up information was used when
applying this method, results from analyses stratified for
baseline dose are also presented in Table 2. As the majority
of the cohort members had a median first dose of 16.7 U
per day (Table 1) these analyses were stratified in three
strata: more than, less than or equal to the median dose per
day. When replacing cumulative exposure at the end of
follow-up with attained cumulative exposure 1 year prior to
the diagnosis of cancer (in order to minimise the chance of
reverse causation) the point estimates remained statistically
significantly protective. Proportionality of the full model
was tested; p values for insulin glargine and other insulin
analogues were, respectively, 0.14 and 0.32.
When specific cancers were used as endpoints (Table 3)
applying the full model, insulin glargine was associated with
a significantly lower risk of colon cancer but not of other
cancers. In contrast, use of insulin glargine was associated
with an increased risk of breast cancer (HR 1.58, 95% CI
1.22, 2.05) and prostate cancer (HR 2.76, 95% CI 1.32, 5.80)
in comparison with use of human insulin. The complete
analyses for endometrial cancer and pancreatic cancer were
not possible because of the low number of cancer diagnoses.
Furthermore, with regard to the stratified model for the first
prescribed dose, analyses were not possible for some of the
lowest strata because of the low number of cases (≈70% of
the participants received a first dose of 16.7 U per day
[Table 1]). No clear dose effect could be seen over the
different strata of dose. For other insulin analogues, no
increased risk of breast cancer or prostate cancer was seen; in
addition, no decreased risk of colon cancer was found.
However, a decreased risk of bladder cancer as well as
respiratory tract cancer was seen (Table 3).
In users of insulin glargine the dose was not related to
the diagnosis of cancer (crude HR comparing those with an
average DDD higher than the median with those having an
average DDD lower than the median 1.02, 95% CI 0.77,
1.34, HR applying full model 0.98, 95% CI 0.74, 1.29) nor
could this be demonstrated for insulin analogues other than
insulin glargine (crude HR 1.02, 95% CI 0.99, 1.04; HR
applying full model 0.95, 95% CI 0.76, 1.18) or for human
insulin (HR 0.95, 95% CI 0.82, 1.09, HR applying a
comparable full model 0.96, 95% 0.82, 1.12).
Fixed-cohort analyses and propensity-score analyses
For cancer in general, similar estimates were found in the fixed
analyses (ESM Table 3). Comparable estimates were also
gained from the propensity-score analyses; these results are
presented in the ESM results. In the analyses with specific
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cancers as endpoints, the results differed slightly. With
regard to insulin glargine, the decreased risk of colon
cancer and the increased risk of breast cancer were
nearly similar; however, for prostate cancer, no risk
deviations could be found. The results for lung cancer
were comparable, but an increased risk was found for
bladder cancer. With regard to other insulin analogues,
the results were comparable: no increased risk of breast
cancer or prostate cancer was seen and no decreased
risk of colon cancer was found. However, a decreased
risk of bladder cancer as well as respiratory tract cancer
was seen (ESM Table 4). As in the as-treated analyses,
no dose–response relationships could be determined.
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Fig. 2 Participants’ adherence to different types of insulin. Dotted
line, insulin glargine; dotted/dashed line, other insulin analogues; solid
line, human insulin
Table 1 Characteristics of participants using insulin glargine, other insulin analogues or human insulin
Variable Insulin glargine
(n=3,789)
Other insulin
analogues
(n=6,032)
Human insulin
(n=9,516)
Age at first prescription of insulin in yearsa 63.1±13.7 61.8±13.9 65.0±13.5
Sex, n (%)b
Male 1,901 (50.2) 2,931 (48.6) 4,423 (46.5)
Female 1,888 (49.8) 3,101 (51.4) 5,093 (53.5)
Total number of unique other drugs used in the year
before first prescription of insulinc
Mean ± SD 8.8±5.6 8.9±6.0 9.0±6.2
Median (IQR) 8 (5–8) 8 (5–8) 8 (5–8)
Total number of hospitalisations in the year
before first prescription of insulinc
Mean ± SD 0.5 (2.1) 0.6 (1.1) 0.6 (1.1)
Median (IQR) 0 (0–1) 0 (0–1) 0 (0–1)
Number of days of OGLD use in the year before
first prescription of insulin, median (IQR)a
324 (280–350) 320 (235–348) 324 (276–349)
Number of days of OGLD use before first prescription
of insulin as of January 1998, median (IQR)a
1,567 (548–2,474) 1,190 (275–2,134) 1,154 (383–1,090)
Duration of follow-up since first insulin prescription in daysa
Mean ± SD 803±587 1,186±823 1,381±924
Median (IQR) 659 (307–1,176) 813 (344–1,489) 1,629 (755–2,350)
Average daily dose of the first insulin prescription (U)a
Mean ± SD 21.7±13.5 28.1±46.6 26.0±19.8
Median (IQR) 16.7 (16.7–16.7) 16.7 (16.7–33.3) 16.7 (16.7–33.3)
Average daily dose over all insulin prescriptions in U
since first prescriptiona
Mean ± SD 44.1±63.4 15.4±44.5 55.6±112.0
Median (IQR) 34.0 (22.0–50.0) 15.0 (14.0–18.0) 46.0 (26.0–64.0)
Types of insulin, first prescription, n (%)
Fast-acting NA 1,899 (31.5) 1,346 (14.1)
Intermediate fast-acting NA 11 (0.2) 4,479 (47.1)
Intermediate and fast-acting NA 3,065 (50.8) 3,691 (38.8)
Long-acting 3,789 (100.0) 1,056 (17.5) NA
Values are mean SD unless stated otherwise
a p value following linear regression <0.0001
b p value following χ2 test <0.0001
c p value following linear regression not significant
IQR, interquartile range; NA, not applicable
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Discussion
In this study, we found that cumulative use of insulin
glargine was associated with a significantly lower risk of
cancer in general, and of colon cancer specifically, in
comparison with use of human insulin. Similar results were
found for the risk of cancer in general and use of other
insulin analogues in comparison with human insulin. In
contrast, as in other studies, we found an increased risk of
breast cancer for insulin glargine in comparison with
human insulin [16, 19]. However, this has not been
consistently confirmed by others [17, 22–24, 39, 40]. For
insulin analogues other than insulin glargine, no increased
risk of breast cancer was found. With regard to breast
cancer, insulin glargine has shown a significantly higher
proliferative effect on breast cancer cells compared with
human insulin or other insulin analogues [41]. Recently, it
was estimated that the serum of type 1 diabetic patients
containing insulin glargine was 1.11-fold more mitogenic
than human insulin containing serum [42]. Our results for
other specific cancers as outcomes were not consistent, with
the exception of a decreased risk of colon cancer for the use
of insulin glargine and a decreased risk of bladder cancer
and respiratory tract cancer for the use of other insulin
analogues.
It might be hypothesised that the protective effect of
insulin glargine on cancer in general is a result of the lower
dose prescribed to these participants in comparison with the
Table 2 Risk of malignancies in patients using insulin glargine or other insulin analogues in comparison with those using human insulin (as-
treated analysis)
Covariablesa included in the model Insulin glargine Other insulin analogues
HR 95% CI HR 95% CI
None 0.71 0.67, 0.75 0.79 0.76, 0.81
Stratified for dose of first insulin prescription
<Median 0.71 0.56, 0.89 0.87 0.76, 0.98
Median 0.71 0.66, 0.77 0.75 0.72, 0.79
>Median 0.68 0.61, 0.76 0.86 0.82, 0.91
Age, sex 0.72 0.68, 0.76 0.80 0.77, 0.82
Age, sex, calendar time, hospitalisations, unique drugs 0.75 0.71, 0.79 0.84 0.81, 0.87
Full model: age, sex, calendar time, hospitalisations,
unique drugs, use of other insulin
0.75 0.71, 0.80 0.85 0.82, 0.89
Full model, adjusted for time since cessationb 0.72 0.67, 0.76 0.82 0.79, 0.86
Full model, adjusted for days of prior OGLD use
<1 year OGLD use 0.77 0.65, 0.90 0.81 0.74, 0.89
≥1 year OGLD use 0.79 0.74, 0.84 0.93 0.88, 0.98
Full model, adjusted for use of OGLD (time-dependent)
Biguanide 0.75 0.71, 0.80 0.85 0.82, 0.89
SU 0.76 0.71, 0.80 0.85 0.81, 0.88
Other OGLD 0.75 0.71, 0.80 0.85 0.82, 0.89
Full model, adjusted for average DDD 0.75 0.71, 0.80 0.85 0.82, 0.89
Full model, stratified for dose of first insulin prescription
<Median 0.70 0.54, 0.89 0.89 0.74, 1.08
Median 0.79 0.73, 0.85 0.81 0.76, 0.85
>Median 0.72 0.64, 0.80 0.92 0.86, 0.98
Full model including a latency time of 1 yearc 0.76 0.71, 0.81 0.88 0.84, 0.93
a Covariables: age, age at first insulin prescription; calendar time, time since inclusion of participant in PHARMO RLS; hospitalisations, number
of hospitalisations in the year prior to start of insulin; unique drugs, number of unique drugs dispensed in the year prior to start of insulin; days of
prior OGLD use, number of days of OGLD use as of January 1998; use of other insulin, in the analysis of insulin glargine, adjustments were made
for use of other types of insulin as a time-dependent variable and in the analysis of other insulin analogues, adjustments were made for use of
insulin glargine as a time-dependent variable; average DDD, dose calculated over all previous insulin prescriptions
b Time since cessation of insulin glargine, other insulin analogues and/or human insulin in days
cModel included a 1 year latency period: exposure was cumulated up till one year prior to the date of cancer diagnosis; incidence rate (no. of
cancer diagnoses/1,000 patient years) for insulin glargine 6.30; for other insulin analogues 7.90 and for human insulin 9.03
SU, sulfonylurea derivative
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Table 3 Risk of specific cancer in patients using insulin glargine or other insulin analogues in comparison with those using human insulin (as-
treated analysis)
Full modela Insulin glargine Other insulin analogues Human insulin
IR n HR 95% CI IR n HR 95% CI IR
Colon cancer
Full 1.29 18 0.55 0.39, 0.76 2.02 62 1.07 0.93, 1.25 1.90
Full model, adjusted for use of OGLD (time-dependent)
Biguanide 0.72 0.63, 0.85 1.06 0.91, 1.23
SU 0.72 0.62, 0.84 1.08 0.93, 1.26
Other OGLD 0.73 0.63, 0.85 1.07 0.91, 1.26
Full model + average DDD 0.55 0.40, 0.76 0.97 0.81, 1.15
Full model, stratified for dose of first insulin prescription
<Median 0 – 0 –
Median 16 0.30 0.17, 0.54 44 0.89 0.70, 1.14
>Median 2 – 18 0.77 0.59, 1.00
Full model including a latency time of 1 yearb 0.86 12 0.61 0.40, 0.91 1.14 35 1.20 0.97, 1.48 1.58
Bladder cancer
Full 0.79 11 1.89 0.69, 3.21 0.91 28 0.48 0.34, 0.69 1.06
Full model, adjusted for use of OGLD (time-dependent)
Biguanide 0.83 0.68, 1.01 0.80 0.65, 0.98
SU 0.84 0.69, 1.02 0.80 0.66, 0.98
Other OGLD 0.83 0.68, 1.01 0.80 0.66, 0.98
Full model + average DDD 1.38 0.70, 2.70 0.48 0.32, 0.70
Full model, stratified for dose of first insulin prescription
<Median 0 – 1 –
Median 8 2.27 1.24, 4.15 16 0.56 0.39, 0.79
>Median 3 – 11 0.79 0.60, 1.04
Full model including a latency time of 1 yearb 0.50 7 1.09 0.37, 3.24 0.61 19 0.66 0.44, 0.99 0.80
Respiratory tract cancer
Full 1.64 23 1.03 0.84, 1.24 1.89 58 0.64 0.54, 0.77 1.90
Full model, adjusted for use of OGLD (time-dependent)
Biguanide 1.01 0.82, 1.24 0.87 0.78, 0.96
SU 0.97 0.79, 1.20 0.87 0.78, 0.96
Other OGLD 1.02 0.82, 1.25 0.86 0.78, 0.95
Full model + average DDD 0.76 0.61, 0.96 0.64 0.54, 0.77
Full model, stratified for dose of first insulin prescription
<Median 0 – 1 –
Median 15 1.09 0.57, 2.07 34 0.46 0.30, 0.71
>Median 8 1.14 0.79, 1.63 23 0.93 0.80, 1.08
Full model including a latency time of 1 yearb 1.07 15 1.23 0.94, 1.62 1.17 36 0.91 0.73, 1.12 1.32
Prostate cancer
Full 0.99 7 2.76 1.32, 5.80 1.26 19 0.83 0.70, 1.03 1.55
Full model, adjusted for use of OGLD (time-dependent)
Biguanide 2.74 1.29, 5.80 0.84 0.70, 1.03
SU 3.12 1.35, 7.19 0.83 0.70, 1.03
Other OGLD 2.72 1.28, 5.79 0.85 0.73, 1.09
Full model + average DDD 1.01 0.62, 1.73 0.99 0.95, 1.04
Full model, stratified for dose of first insulin prescription
<Median 0 – 0 –
Median 5 2.21 0.92, 5.34 11 0.83 0.53, 1.39
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dose prescribed to participants using other insulin ana-
logues or human insulin. Adjustment for dose was
performed by adding dose as a time-dependent covariable
in the model. Using this method, follow-up information is
used, which is prone to reverse causality bias. Therefore,
analyses were stratified for the baseline dose. However, in
these stratified analyses as well as separate dose analyses,
no dose-dependent relations could be demonstrated.
Our results are partly at variance with the earlier
published population-based studies that caused alarm [16–
20]. The first of these papers concluded that risk of cancer
in participants using insulin glargine was higher than in
those using human insulin [18]. As a possible explanation,
the mitogenic properties of insulin glargine in diabetic
patients, as published earlier, were suggested [43]. Another
study reported that insulin analogues were not associated
with a higher incidence of cancer compared with human
insulin [17]. The third one, a Swedish study, did not show
an increased risk of any malignancy, but similar to our
study, they showed that women using insulin glargine had
an increased incidence rate of breast cancer compared with
women using other types of insulin analogues or human
insulin [19]. The Scottish Diabetes Research Network found
that those receiving insulin glargine had the same incidence
rate for all cancers as those not receiving insulin glargine [16].
However, a subset of patients using insulin glargine alone
had a significantly higher incidence of all cancers, and breast
cancer specifically, than those using other types of insulin
[16]. Nevertheless, the authors concluded that insulin
glargine use was most likely not associated with an increased
risk of cancer and that the finding above should be
considered to be biased because of differences in allocation
of patients to different types of insulin [16]. More recently, a
cohort study of new users of OGLDs showed that the
number of insulin doses dispensed (any insulin type) was
associated with a higher risk of cancer compared with
participants not using insulin [44]. In contrast, it was
reported that, in a Taiwanese cohort study [20], use of
insulin glargine was not associated with an increased risk of
overall cancer while in Chinese individuals with type 2
diabetes, insulin usage (any type) was associated with a
reduced risk of cancer compared with non-usage [45].
However, the latter study was severely criticised for the
exclusion of follow-up time prior to insulin use [25].
Limitations of the earlier publications were brought
forward, among which were short follow-up, failure to correct
for body mass index, the impossibility of breaking down the
risk of cancer in general to a tumour-specific risk, the inability
to consider prior use of insulin before start of study, low
numbers of patients using a specified insulin and the absence
of dose analyses [32]. In addition, clinical decisions
determining each patient’s treatment are not random and
Table 3 (continued)
Full modela Insulin glargine Other insulin analogues Human insulin
IR n HR 95% CI IR n HR 95% CI IR
>Median 2 – 8 0.87 0.67, 1.16
Full model including a latency time of 1 yearb 0.71 5 2.19 1.03, 4.66 0.79 12 0.84 0.68, 1.43 1.15
Breast cancer
Full 4.06 28 1.58 1.22, 2.05 3.08 48 0.95 0.83, 1.08 2.81
Full model, adjusted for use of OGLD (time-dependent)
Biguanide 1.58 1.22, 2.04 0.94 0.81, 1.08
SU 1.67 1.28, 2.19 0.94 0.82, 1.08
Other OGLD 1.52 1.16, 1.98 1.03 0.89, 1.20
Full model + average DDD 1.62 1.24, 2.12 0.90 0.80, 1.02
Full model, stratified for dose of first insulin prescription
<Median 2 – 3 –
Median 15 1.22 0.91, 1.64 29 0.90 0.70, 1.15
>Median 11 2.81 1.23, 6.44 16 0.10 0.02, 0.47
Full model including a latency time of 1 yearb 1.60 11 1.65 1.10, 2.47 1.99 31 0.99 0.81, 1.20 2.28
a In the full model, adjustments were made for age at first insulin prescription, sex, calendar time, number of unique drugs used in the year before
start of insulin and number of hospitalisations in the year before start of insulin. Days of prior OGLD use, number of days of OGLD use as of
January 1998. Furthermore, when the insulin of interest was insulin glargine, adjustments were made for the use of other insulin analogues as
time-dependent variables; when the insulin of interest were other insulin analogues, adjustments were made for the use of insulin glargine
bModel included a 1 year latency period: exposure was cumulated up till one year prior to the date of cancer diagnosis
IR, incidence rate; n, number of events; SU, sulfonylurea derivative
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confounding by severity of glucose intolerance could play an
important role in observational studies [28, 30]. Another
issue is reverse causality and assessment of aetiologically
relevant timing of exposure: cancer has a long latency period
during which the disease itself may cause changes in
treatment [28, 30]. Last, the severity of disease may also
be related to the frequency of clinical contact, which may
reduce the time between onset and diagnosis of cancer [28].
As described above, reverse causality may play a role in
observational studies, as cancer often has a long latency
period between the biological onset of the disease and the
clinical diagnosis. During this latency period, symptoms
related to still undetected cancer may lead to treatment
changes. By cumulating exposure to 1 year prior to the
diagnosis of cancer, we attempted to minimise reverse
causality by taking into account a latent period (i.e. when
the disease is already present but not yet diagnosed). To
further address reverse causation, we performed a fixed
analysis; none of these analyses changed the risk of cancer
in general by more than 10%. To address the issue of
potential residual confounding a propensity-score analysis
was performed from which similar estimates were found.
Also, although we assumed that cancer risk does not return
to the background rate after a certain cumulative exposure,
we performed a sensitivity analysis in which we adjusted
for time since cessation. This adjustment was done to
investigate whether the risk declined after discontinuation.
However, this did not substantially change the risk estimates.
Our study was performed in incident users of insulin:
those who had a prescription-free period of 6 months before
study entry. By excluding those with prevalent use of
insulin, we attempted to make participants more compara-
ble with regard to duration and severity of insulin
resistance. However, the participants being prescribed
insulin glargine differed considerably from those being
prescribed other insulin analogues or human insulin. Insulin
glargine is reserved for those suffering from nightly
hypoglycaemic attacks, partly because of its higher cost in
comparison to human insulin [37]. Patients with type 1
diabetes are particularly prone to these attacks as, in
contrast to patients with type 2 diabetes, they do not have
any remaining insulin production [1]. However, it is
possible that under everyday circumstances in the Nether-
lands, insulin glargine is prescribed more generally to those
having difficulties attaining euglycaemia. Unfortunately, we
were not able to fully differentiate between those receiving
insulin for type 1 or for type 2 diabetes; these groups might
differ regarding their cancer risk. However, in an attempt to
restrict the analysis to those with type 2 diabetes, we included
only participants with prior OGLD use. We were able to adjust
for the number of unique other drugs used prior to the first
prescription of insulin and the number of hospitalisations to
adjust for comorbidity. Nevertheless, it is likely that our
findings are confounded as those receiving insulin glargine or
other insulin analogues might die earlier because of comorbid-
ity; consequently they would not live long enough to develop
cancer or, in other words, they would die of ‘competing risks’
[46]. Another explanation for our findings might be the
significantly lower adherence to insulin glargine in compar-
ison with use of other insulin analogues or human insulin.
In contrast to some former studies, we were not able
to adjust for smoking status or body mass index, which
might be considerable confounding factors. However,
although obesity is associated with an increased risk of
developing insulin resistance and type 2 diabetes [47]
caution must be made when assessing the relationship
with cancer. Furthermore, in previous studies, smoking
and body mass index did not change the point estimate by
more than 10% [16, 19].
Last, in our study we used cancer hospitalisation as an
outcome measure, which is different from pathology data
for cancer diagnoses. Some cancers might be diagnosed
more frequently in a non-clinical setting. Within each
specific cancer, this would, however, lead to non-
differential misclassification of the outcome and conse-
quently to dilution of the estimated effect towards the null
hypothesis.
In conclusion, in our study of insulin users, users of
insulin glargine had a lower risk of specific cancers and of
cancer in general in comparison with those on human
insulin. Similar results were found for use of other insulin
analogues in comparison with human insulin. However, in
our opinion, both associations might be a consequence of
residual confounding, lack of adherence or competing risk.
The fact that we were not able to demonstrate a dose–effect
association would also be an argument against a causal
relationship. Furthermore, as in previous studies, we
demonstrated an increased risk for breast cancer and use
of insulin glargine [16, 19]. In our opinion, reasons for
concern with regard to the safety of insulin glargine remain
and the possible association with cancer, and breast cancer
specifically, requires further attention.
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